Prevalence and clinical correlates of elevated high-sensitivity C-reactive protein in patients presenting with acute coronary syndrome: a single-center retrospective study

BACKGROUND: High-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation. The frequency of hsCRP >2 mg/L, a threshold used in anti-inflammatory trials, among patients presenting with acute coronary syndrome (ACS) is incompletely characterized. METHODS: We retrospectively analyzed consecutive patients presenting with ACS at Sismanoglio General Hospital of Athens between January 2023 and May 2024 who had hsCRP measured on arrival. We assessed the frequency and magnitude of hsCRP elevation, clinical and laboratory associations, and factors associated with hsCRP >2 mg/L after adjustment for age. RESULTS: Of 103 patients, 93 (90.3%) had hsCRP measured and were included (median age: 65 years; interquartile range: 58-73; 84.9% male). Elevated hsCRP (>2 mg/L) occurred in 67.7%, and 25.8% had hsCRP >10 mg/L. Median hsCRP was 3.8 mg/L (interquartile range: 1.3-10.2), without a significant difference between ST-segment elevation and non-ST-segment elevation myocardial infarction presentations (3.2 vs. 6.0 mg/L; P = 0.15). After mutual adjustment and adjustment for age, diabetes (adjusted odds ratio: 4.46; 95% confidence interval: 1.40-14.15; P = 0.011) and current smoking (adjusted odds ratio: 4.74; 95% confidence interval: 1.65-13.59; P = 0.004) remained associated with elevated hsCRP. CONCLUSIONS: Two-thirds of patients had hsCRP >2 mg/L at ACS presentation. Diabetes and smoking were independently associated with elevation. These findings quantify the proportion meeting an inflammatory trial entry criterion but do not establish persistent inflammation or support anti-inflammatory treatment. Prospective studies with serial measurements and clinical outcomes are needed to determine whether elevation persists and identifies modifiable risk.

Authors

Institutions

Publication Details

Journal
Coronary Artery Disease
Published
2026-11-16
DOI
https://doi.org/10.1097/mca.0000000000001686
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prevalence and clinical correlates of elevated high-sensitivity C-reactive protein in patients presenting with acute coronary syndrome: a single-center retrospective study

Nikolaos Tsiamis, Δημήτριος Ζαχαράκης, Sotirios C. Kotoulas, Toutouzas Konstantinos et al.
1 links
Coronary Artery Disease
Acute Myocardial Infarction Research
article

Prevalence and clinical correlates of elevated high-sensitivity C-reactive protein in patients presenting with acute coronary syndrome: a single-center retrospective study

Nikolaos Tsiamis, Δημήτριος Ζαχαράκης, Sotirios C. Kotoulas, Toutouzas Konstantinos, Dimitrios Afendoulis, Asimina Romiou, Απόστολος Κακκάβας, Christo Kole, Sotirios Tsalamandris, Christos Tountas, Anastasia Kitsiou, Athanasios Kartalis, Eleni Michailidi
article en

Abstract

BACKGROUND: High-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation. The frequency of hsCRP >2 mg/L, a threshold used in anti-inflammatory trials, among patients presenting with acute coronary syndrome (ACS) is incompletely characterized. METHODS: We retrospectively analyzed consecutive patients presenting with ACS at Sismanoglio General Hospital of Athens between January 2023 and May 2024 who had hsCRP measured on arrival. We assessed the frequency and magnitude of hsCRP elevation, clinical and laboratory associations, and factors associated with hsCRP >2 mg/L after adjustment for age. RESULTS: Of 103 patients, 93 (90.3%) had hsCRP measured and were included (median age: 65 years; interquartile range: 58-73; 84.9% male). Elevated hsCRP (>2 mg/L) occurred in 67.7%, and 25.8% had hsCRP >10 mg/L. Median hsCRP was 3.8 mg/L (interquartile range: 1.3-10.2), without a significant difference between ST-segment elevation and non-ST-segment elevation myocardial infarction presentations (3.2 vs. 6.0 mg/L; P = 0.15). After mutual adjustment and adjustment for age, diabetes (adjusted odds ratio: 4.46; 95% confidence interval: 1.40-14.15; P = 0.011) and current smoking (adjusted odds ratio: 4.74; 95% confidence interval: 1.65-13.59; P = 0.004) remained associated with elevated hsCRP. CONCLUSIONS: Two-thirds of patients had hsCRP >2 mg/L at ACS presentation. Diabetes and smoking were independently associated with elevation. These findings quantify the proportion meeting an inflammatory trial entry criterion but do not establish persistent inflammation or support anti-inflammatory treatment. Prospective studies with serial measurements and clinical outcomes are needed to determine whether elevation persists and identifies modifiable risk.

Coronary Artery Disease
National and Kapodistrian University of Athens (GR), Sismanoglio General Hospital (GR), General Hospital Asklepieio Voulas (GR), Hippocration General Hospital (GR)
Good health and well-being
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon